Elevated levels of platelet–monocyte aggregates and related circulating biomarkers in patients with acute coronary syndrome

Wang, Junhong; Zhang, Songzhao; Jin, Yifan; Qin, Guangming; Yu, Lei; Zhang, Jinan

doi:10.1016/j.ijcard.2006.03.019

Cited by 63 publications

(46 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In previous studies, high monocyte count was shown to be significantly associated with cardiovascular prognosis including mortality in STEMI [11,12]. Increased circulating platelet-monocyte aggregates were observed in patients with acute coronary syndromes [13,14], which could induce expression and release of chemotactic factors, including monocyte-chemoattractant-protein-1 (MCP-1) and interleukin-8 (IL-8) from monocytes [15]. Besides activation of monocyte adhesion onto endothelial cells, MCP-1 induces the expression of tissue factor, superoxide anions, and exerts prothrombotic effects [16,17].…”

Section: Discussionmentioning

confidence: 90%

Association of monocyte count on admission with angiographic no-reflow after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction

et al. 2016

View full text Add to dashboard Cite

A b s t r a c t Background:The no-reflow phenomenon during primary percutaneous coronary intervention (pPCI) in patients with ST-elevation myocardial infarction (STEMI) can lead to poor outcomes. It has been shown that the monocytes may be involved in the pathogenesis of coronary artery disease and associated with high risk of myocardial infarction. Aim:To assess the relation between admission monocyte count and angiographic no-reflow after pPCI. Methods:A total of 236 patients with acute STEMI, who underwent pPCI, were enrolled. The patients were divided into two groups (no-reflow and normal reflow) based on post-pPCI Thrombolysis in Myocardial Infarction (TIMI) flow grade. No reflow was defined as TIMI flow grades ≤ 2, and normal reflow was defined as TIMI 3 flow grade. The monocyte count and other laboratory parameters were measured on admission before pPCI. Conclusions:Monocyte count on admission and low haemoglobin concentration were independent clinical predictors of no-reflow following pPCI in patients with STEMI. Our findings suggest that admission monocyte count may be available for early risk stratification of no-reflow after pPCI and might allow the improvement of strategies to prevent this phenomenon.

show abstract

Section: Discussionmentioning

confidence: 90%

Association of monocyte count on admission with angiographic no-reflow after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction

et al. 2016

View full text Add to dashboard Cite

show abstract

“…It initiates the production of reactive oxygen species that are important for the development of atheroma and plaque rupture (28). Thus, an increased level of MPO is a marker of plaque instability (29). Furthermore, it serves as a predictive marker for future cardiovascular adverse events (30).…”

Section: Myeloperoxidase (Mpo)mentioning

confidence: 99%

Diagnostic markers of acute myocardial infarction

2015

View full text Add to dashboard Cite

Abstract. Acute myocardial infarction (AMI) is a major cause of morbidity and mortality worldwide. The highest risk of fatality occurs within the initial hours of onset of AMI. Thus, early diagnosis of cardiac ischemia is critical for the effective management of patients with AMI. Improper diagnosis of patients with chest pain often leads to inappropriate admission of patients without AMI and vice versa. In addition to clinical history, physical examination, accurate electrocardiogram findings and assessment of cardiac biomarkers have an important role in the early diagnosis of acute ischemia. The present review discusses in detail the various cardiac biomarkers released during the event of an AMI.

show abstract

“…These biomarkers have the potential to allow for extremely early diagnosis of AMI, before increases in biomarkers of necrosis, even when highly sensitive troponin (cTn) assays using contemporary cutoff values are employed. We analyzed a panel of proteins that have been implicated in the events leading to AMI [1,[4][5][6][7][8][9][10][11]. Accordingly, we measured biomarkers thought to be involved in vascular inflammation, plaque destabilization and myocardial dysfunction to determine if different proteins and their combinations could be used synergistically to identify patients that subsequently would develop myocardial necrosis.…”

Section: Introductionmentioning

confidence: 99%

“Upstream markers” provide for early identification of patients at high risk for myocardial necrosis and adverse outcomes

Kavsak

Newman

et al. 2008

Clinica Chimica Acta

View full text Add to dashboard Cite

Background-For patients presenting with acute coronary syndrome (ACS) to the emergency department, early identification of those that are at high risk for subsequent myocardial necrosis or adverse outcomes would allow earlier or more aggressive treatment. We determined if a panel of biomarkers can be used to identify high risk patients.Methods-A cohort (84 females/132 males) from our 1996 ACS study population that had EDTA specimens stored (−70 °C) was selected and the earliest available specimen was analyzed for 11 biomarkers (IL-6, IL-8, MCP-1, VEGF, L-selectin, P-selectin, E-selectin, ICAM-1, VCAM-1, NT-proBNP, cTnT). These data were linked to the existing cTnI and health outcome databases for this population. ROC curve analysis for myocardial necrosis (i.e., peak cTnI >0.04 μg/l) identified 3 candidate biomarkers. These 3 biomarkers were applied together to generate a panel test (2 of the 3 biomarkers increased for a positive result) and assessed for its ability to identify patients at risk for myocardial necrosis and the combined endpoint of death, myocardial infarction (MI) and heart failure (HF).Results-The panel test (IL-6, NT-proBNP, E-selectin) alone detected 60% (95% CI: 49-69; false positive rate: 26%) of subjects that would be classified with myocardial necrosis. KaplanMeier and Cox proportional analyses indicated that patients positive by the biomarker panel (including those with cTnI ≤0.04 μg/l) had significantly worse outcomes (death/MI/HF) as compared to those negative by both cTnI and the panel test. CIHR Author Manuscript CIHR Author Manuscript CIHR Author ManuscriptConclusion-A biomarker panel analyzed early after pain onset can identify individuals at risk for both myocardial necrosis and the combined endpoint of death/MI/HF. Additional prospective studies are required to assess this panel for both early MI detection and to further refine which health outcomes (death, MI, HF) are associated with positive panel results.

show abstract

Elevated levels of platelet–monocyte aggregates and related circulating biomarkers in patients with acute coronary syndrome

Cited by 63 publications

References 24 publications

Association of monocyte count on admission with angiographic no-reflow after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction

Association of monocyte count on admission with angiographic no-reflow after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction

Diagnostic markers of acute myocardial infarction

“Upstream markers” provide for early identification of patients at high risk for myocardial necrosis and adverse outcomes

Contact Info

Product

Resources

About